Credit Suisse Ag Kronos Bio, Inc. Transaction History

Credit Suisse Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$1.44 - $3.44 $329 - $787	-229 Reduced 99.13%	2 $0
Q3 2022 Nov 10, 2022	BUY	$3.35 - $5.55 $636 - $1,054	190 Added 463.41%	231 $1,000
Q2 2022 Aug 12, 2022	SELL	$3.12 - $7.52 $38,641 - $93,135	-12,385 Reduced 99.67%	41 $0
Q1 2022 May 16, 2022	SELL	$6.26 - $14.42 $8,163 - $18,803	-1,304 Reduced 9.5%	12,426 $89,000
Q4 2021 Feb 14, 2022	SELL	$11.35 - $21.18 $267,054 - $498,344	-23,529 Reduced 63.15%	13,730 $187,000
Q3 2021 Nov 12, 2021	BUY	$18.17 - $24.7 $520,625 - $707,729	28,653 Added 332.94%	37,259 $780,000
Q2 2021 Aug 16, 2021	BUY	$20.08 - $29.02 $172,808 - $249,746	8,606 New	8,606 $206,000

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.